RSS Feeds
Search

Companies

Leiras Takeda Pharmaceuticals

Leiras Takeda Pharmaceuticals
TAKEDA, Regional Business Development, new; near to market presciption drugs for region Nordic countries

The company in detail

Profile

On October 1st 2011 TAKEDA bought NYCOMED, the previous parent company of LEIRAS. Nowadays LEIRAS and its three legacy NYCOMED sister companies in Scandinavia are fully integrated part of the global pharma company TAKEDA

At TAKEDA Nordics, we are applying Cluster Concept, meaning that certain functions are shared between different affiliates acting in same region. Business Development is one of those co-ordinated functions. The licensing and negotiation work is carried per product catagories ( prescription and self care product areas separately, with separate responsible business development persons ). 

We at Takeda are looking for new chemical prescription substances and new value added prescription products for the region covering all Nordic markets (Finland, Sweden, Norway and Denmark).

Nordic region represents a remarkable market segment in European market with it´s total value close to 9 billion Euro. In Takeda Nordic licensing process, the preference is to be able to licese new product for all four Nordic countries, but even pure single market opportunities will be fully evaluated.

TAKEDA has strong market position in all Nordic markets (sales more than Euro 250 million) , through it´s bought legacy NYCOMED affilaites, covering both primary and hospital care prescription drugs, and having strong OTC presence as well.  We have strong sales forces in all Nordic countries and appropriate marketing function providing support for the sales force. TAKEDAs own global R&D and corporate licensing provide together the back bone  of new products pipeline. Our regional in-licensing is represents a very important role in our regional portfolio development and alliance management.

TAKEDA in Nordics, is  ready to make quick and full medical and market assesment for regional in-licensing product opportunities. If you have prescription drug available for licensing in Nordics, please make your contact to Mr Raimo Skottman  ( raimo.skottman@takeda.com

Further info about TAKEDA (www.takeda.com) or (www.leiras.fi/english )

Partnering strategy/interests

We at Takeda are looking for new chemical prescription substances and new value added prescription products for the region covering all Nordic markets (Finland, Sweden, Norway and Denmark).

Our general requirements for new prescription drugs are:
1) drugs developed at least up to phase III, or NDA ready, or submitted for MA approval
     or even Marketing Authorization granted 
2) product does not require TAKEDAs participation / co-funding & commitment on new clinical trials
3) drug serves unmet medical need
4) drug has patent coverage available for number of years ahead
5) drug is directed mainly to specialist 6) product is available as finished goods and released in EU area by supplier

Our current therapeutic focus for new prescription drugs in Nordic countries lies on 1) renal diseases 2) CNS diseases 3) Inflammatory bowel diseses 4) oncology 5) diabetes and 6) respiratory diseases. On these therepeutic areas, new innovative product should act as complimentary product / or as new product form, for our existing or coming products in our group pipeline.

The licensing and negotiation work is carried per product catagories ( prescription and self care product areas separately, with separate responsible business development persons ). TAKEDA in Nordics, is  ready to make quick and full medical and market assesment for regional in-licensing product opportunities. If you have prescription drug available for licensing in Nordics, please make your contact to Mr Raimo Skottman  ( raimo.skottman@takeda.com

 

 

Contact details

Mr Raimo Skottman
Director, Business Development
prescription drugs, TAKEDA Nordic countries

Contact directly

Full contact list

Head office

Leiras Takeda Pharmaceuticals
Paciuksenkatu 21 (LEIRAS)
PO Box 1406
Helsinki
FINLAND
FIN-00101
Finland

Company figures

Formed: 1876
Annual Turnover: 15 billion (2011)
Number of employees: 30000

Related categories

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2014 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us